Archives of Pharmacology and Therapeutics

Therapeutic compliance has been defined as the degree to which the behaviour of a person corresponds with the recommendations of the health professional [1].

Diagnosis is a process that identifies, explains, or establishes the individual’s disease from its symptoms and signs. Early and precise diagnosis is crucial since it influences the efficacy of treatment and avoids longterm complications for the infected person. Further, in the case of infectious diseases, undiagnosed patients can transmit the disease to a healthy population unknowingly. Besides, most of the diseases evolve with the time that significantly affects the clinical outcomes.

Behavioral interventions with regular physical activity, weight loss and diet have repeatedly demonstrated preventive effects in a wide range of diseases. Furthermore, an unhealthy lifestyle is a known predictor for increased use of medication and also the leading risk factor for global mortality.

The precise role of corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is unclear due to lack of randomized trials.

Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.

Fluoropyrimidines have been extensively used for almost 6 decades to treat a variety of solid cancers, especially colon, gastric, anal, rectal, head & neck and breast. However, 31–34% of patients encountered grade 3–4 adverse events (AEs) with 0.5% mortality oftennecessitating dose reduction or discontinuation. 

In pharmacologic doses niacin (nicotinic acid) has been used clinically for over six decades for atherogenic dyslipidemia and reduction of cardiovascular event risk. In combination with statin therapy, it effects regression of coronary atherosclerosis. Emerging evidence indicates a new potential use for niacin for the treatment of NAFLD and its complications. Despite this enormous amount of data on niacin, there is confusion and misconceptions about its use of a drug rather than as a vitamin, its formulations, and how it can be used in clinical practice. The purpose of this invited brief communication is to update and summarize this emerging evidence. We comment on how it may be valuable in the context of other drugs-in-development for NAFLD, especially for combination therapy for synergistic efficacy.

After one year in a pandemic, we mourn the loss of over half a million lives in the United States, and over four million worldwide, and remain concerned over the challenges facing the families of 35 million people in the United States, and 200 million worldwide, who have suffered from cases of COVID-19.

Cancer is the second most common cause of death worldwide, accounting for an estimated 9.6 million deaths in the year 2018, a number that is expected to grow to more than 13 million by 2030. In the past decade, we have witnessed unprecedented scientific advancement in the understanding of cancer etiology, prevention, diagnosis and development of new therapeutic strategies.

In light of the current pandemic from rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) and significant morbidity, there has been inconsistent medical guidance given to the public regarding the wearing of non-medical improvised fabric masks or face coverings to reduce the transmission of COVID-19.

Over the past few years, pharmaceutical R&D has become aware of the potential benefits of leveraging artificial intelligence and its collective subfields including machine learning, deep learning, data science and advanced analytics.

At the beginning of Covid-19 pandemic, we proposed to use hydroxychloroquine (HCQ) and intranasal interferon (IFN) a-2b spray to prevent SARS-CoV-2.

Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacille Calmette-Guerin (BCG) and chemotherapy.

Stroke is a major cause of death and disability in the world. There were approximately 25.7 million stroke survivors and 6.5 million deaths from stroke [1]. Stroke can result in arm disability and reduce daily life activity via weak arm muscle activity [2]. Studies have been performed to discover therapeutic and assistive approaches to compensate for disabilities and restore functions. 

The prevalence of diabetes in COVID-19 patients ranges from 5.3% to 58% representing the second comorbidity after hypertension. However, when adjusted for age, diabetes prevalence among COVID-19 patients is similar to its prevalence in the general population.

COVID-19 has challenged global health and affected many countries. The disease had infected more than 16 million people and killed over 650,000 ones by the end of July 2020. According to Sahu et al., COVID-19 epidemic is the third most common coronavirus in the 21st century, resulting in numerous deaths all over the world. It has caused severe psychological stress and increased hospital visits along with increased tiredness and burnout of medical staff. The disease has also raised many problems for the management of hospitals and diagnostic-treatment centers, so that many of them have no capacity to receive patients.

Additive manufacturing has the potential to revolutionize the pharmaceutical industry, enabling the production of customized drugs for the mass market. However, concerns over scalability, low mechanical resistance, low printing resolution and limited material choices have so far hindered the practical application of current 3D printing (3DP)

The present Commentary is a critical follow-up of a previous review about “Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases”, appeared in Clinical and Experimental Immunology last June 2019 [1].

The outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to coronavirus disease-19 (COVID-19); a pandemic disease that has resulted in devastating social, economic, morbidity and mortality burdens. SARS-CoV-2 infects cells following receptor-mediated endocytosis and priming by cellular proteases.

Ectodomain shedding mediated by a disintegrin and metalloprotease 10/17 (ADAM10/17) modulates the function of immune effector cells and may be involved in the novel coronavirus disease COVID-19. Toll-like receptor 7/8 (TLR7/8) recognizes single-strand RNA from viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19) during the innate immune response